PODD · Insulet Corp · Webcasts, Transcripts & Audio
$152.48
+3.19 (+2.14%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$10.58B
Shares
69.37M
Volume · Nov 13
1.59M
Avg daily vol (3M)
1.57M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Insulet Corp Webcasts
Earnings calls, investor updates, investor days and conferences for Insulet Corp (PODD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-18
Insulet Corp (PODD) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
Insulet Corp (PODD) Q3 2026 Earnings Call Transcript
Confident tone
Omnipod 6 and product innovation
Type 2 retention and customer experience
International performance
Revenue
$842.00M
▲ 19.2% YoY Diluted EPS
$2.03
▲ 63.7% YoY Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
Insulet Corp (PODD) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Insulet Corp (PODD) Q2 2026 Earnings Call Transcript
Positive tone
Type 2 diabetes customer dynamics
Omnipod 5 commercial performance
2026 financial outlook
Revenue
$801.70M
▲ 23.5% YoY Diluted EPS
$1.37
▲ 328.1% YoY Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Insulet Corp (PODD) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
Insulet Corp (PODD) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Insulet Corp (PODD) Q1 2026 Earnings Call Transcript
Confident tone
U.S. Market Performance and Seasonality
Revenue Growth and Guidance Raise
Type 2 Diabetes Expansion
Revenue
$761.70M
▲ 33.9% YoY Diluted EPS
$1.30
▲ 160% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-18
Insulet Corp (PODD) Q4 2025 Earnings Call Transcript
Confident tone
U.S. type 1 market leadership
U.S. type 2 expansion opportunity
Competitive moats and commercial capabilities
Revenue
$783.70M*
▲ 31.2% YoY Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Insulet Corp (PODD) Q3 2025 Earnings Call Transcript
Confident tone
Type 2 Expansion
U.S. Type 1 Market Leadership
International Growth
Revenue
$706.30M
▲ 29.9% YoY Diluted EPS
$1.24
▲ 14.8% YoY Gross margin
72.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Insulet Corp (PODD) Q2 2025 Earnings Call Transcript
Confident tone
U.S. Type 2 market expansion
Omnipod 5 clinical differentiation and prescriber base
International growth and Omnipod 5 conversion
Revenue
$649.10M
▲ 32.9% YoY Diluted EPS
$0.32
▼ 87.6% YoY Gross margin
69.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Insulet Corp (PODD) Q1 2025 Earnings Call Transcript
Confident tone
Omnipod 5 and innovation pipeline
New CEO leadership transition
U.S. type 2 expansion
Revenue
$569.00M
▲ 28.8% YoY Diluted EPS
$0.50
▼ 31.5% YoY Gross margin
71.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Insulet Corp (PODD) Q4 2024 Earnings Call Transcript
Confident tone
Omnipod 5 adoption and customer milestones
Gross margin and manufacturing
Omnipod Discover launch
Revenue
$597.50M*
▲ 17.2% YoY Gross margin
72.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Insulet Corp (PODD) Q3 2024 Earnings Call Transcript
Confident tone
Omnipod 5 Platform and Innovation
New Customer Starts
International Expansion
Revenue
$543.90M
▲ 25.7% YoY Diluted EPS
$1.08
▲ 45.9% YoY Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Insulet Corp (PODD) Q2 2024 Earnings Call Transcript
Confident tone
Omnipod 5 growth and momentum
International expansion
Type 2 diabetes opportunity
Revenue
$488.50M
▲ 23.2% YoY Diluted EPS
$2.59
▲ 564.1% YoY Gross margin
67.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Insulet Corp (PODD) Q1 2024 Earnings Call Transcript
Confident tone
International expansion (U.K., Germany, France, Netherlands)
GLP-1 impact on insulin adoption
Sensor integrations (Dexcom G7, Abbott Libre 2 Plus)
Revenue
$441.70M
▲ 23.3% YoY Diluted EPS
$0.73
▲ 114.7% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Insulet Corp (PODD) Q4 2023 Earnings Call Transcript
Confident tone
Omnipod 5 growth and market leadership
Type 2 diabetes opportunity
Financial results and margin expansion
Revenue
$509.80M*
▲ 37.9% YoY Gross margin
70.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Insulet Corp (PODD) Q3 2023 Earnings Call Transcript
Revenue
$432.70M
▲ 27% YoY Diluted EPS
$0.74
Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Insulet Corp (PODD) Q2 2023 Earnings Call Transcript
Revenue
$396.50M
▲ 32.4% YoY Diluted EPS
$0.39
Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Insulet Corp (PODD) Q1 2023 Earnings Call Transcript
Revenue
$358.10M
▲ 21.2% YoY Diluted EPS
$0.34
▼ 15% YoY Gross margin
67.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Insulet Corp (PODD) Q4 2022 Earnings Call Transcript
Revenue
$369.70M*
▲ 20.1% YoY Gross margin
58.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Insulet Corp (PODD) Q3 2022 Earnings Call Transcript
Revenue
$340.80M
▲ 23.7% YoY Diluted EPS
$-0.08
▼ 144.4% YoY Gross margin
55.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Insulet Corp (PODD) Q2 2022 Earnings Call Transcript
Revenue
$299.40M
▲ 13.8% YoY Diluted EPS
$-0.50
Gross margin
63.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Insulet Corp (PODD) Q1 2022 Earnings Call Transcript
Revenue
$295.40M
▲ 17.1% YoY Diluted EPS
$0.40
Gross margin
71.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Insulet Corp (PODD) Q4 2021 Earnings Call Transcript
Revenue
$307.70M*
▲ 25% YoY Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Insulet Corp (PODD) Q3 2021 Earnings Call Transcript
Revenue
$275.60M
▲ 17.8% YoY Diluted EPS
$0.18
▲ 5.9% YoY Gross margin
68.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Insulet Corp (PODD) Q2 2021 Earnings Call Transcript
Revenue
$263.20M
▲ 16.3% YoY Diluted EPS
$-0.37
▼ 268.2% YoY Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Insulet Corp (PODD) Q1 2021 Earnings Call Transcript
Revenue
$252.30M
▲ 27.4% YoY Diluted EPS
$0.00
Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Insulet Corp (PODD) Q4 2020 Earnings Call Transcript
Revenue
$246.10M*
▲ 17.5% YoY Gross margin
65.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Insulet Corp (PODD) Q3 2020 Earnings Call Transcript
Revenue
$234.00M
▲ 21.8% YoY Diluted EPS
$0.17
▲ 1600% YoY Gross margin
64.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Insulet Corp (PODD) Q2 2020 Earnings Call Transcript
Revenue
$226.30M
▲ 27.8% YoY Diluted EPS
$0.22
▲ 1000% YoY Gross margin
63.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Insulet Corp (PODD) Q1 2020 Earnings Call Transcript
Revenue
$198.00M
▲ 24.1% YoY Diluted EPS
$-0.03
▼ 142.9% YoY Gross margin
64.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Insulet Corp (PODD) Q4 2019 Earnings Call
Revenue
$209.40M
▲ 27% YoY Diluted EPS
$0.08
▼ 50% YoY Gross margin
64.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 webcasts
Key facts
CIK
1145197
CUSIP
45784P101
13F (30d)
547 filings
504 filers
Visit website
Investor relations